Bioventus (BVS) Financials

$6.56 +0.03 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$6.65 +0.09 (+1.37%)

As of 06:03 PM Eastern

Annual Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-34	-156	-159
Consolidated Net Income / (Loss)	-44	-196	-213
Net Income / (Loss) Continuing Operations	-44	-121	-145
Total Pre-Tax Income	-49	-121	-189
Total Operating Income	-12	-82	-167
Total Gross Profit	388	328	331
Total Revenue	573	512	512
Operating Revenue	573	512	512
Total Cost of Revenue	185	184	181
Operating Cost of Revenue	185	184	181
Total Operating Expenses	400	410	498
Selling, General & Admin Expense	341	304	332
Research & Development Expense	14	13	24
Depreciation Expense	7.65	8.84	9.75
Other Operating Expenses / (Income)	0.29	3.58	0.00
Impairment Charge	36	79	125
Restructuring Charge	-0.05	0.84	6.78
Other Special Charges / (Income)	1.42	0.72	1.10
Total Other Income / (Expense), net	-37	-39	-22
Interest & Investment Income	-39	-41	-12
Other Income / (Expense), net	1.65	1.29	-9.77
Income Tax Expense	-5.29	0.09	-44
Net Income / (Loss) Discontinued Operations	0.00	-74	-69
Net Income / (Loss) Attributable to Noncontrolling Interest	-10	-39	-55
Basic Earnings per Share	($0.52)	($2.49)	($2.59)
Weighted Average Basic Shares Outstanding	64.55M	62.65M	61.39M
Diluted Earnings per Share	($0.52)	($2.49)	($2.59)
Weighted Average Diluted Shares Outstanding	64.55M	62.65M	61.39M
Weighted Average Basic & Diluted Shares Outstanding	81.94M	79.17M	78.05M

This table shows Bioventus' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/28/2024	6/29/2024	3/30/2024	12/31/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.16	-4.82	-24	-4.57	-6.10	-7.30	-3.68	-139	-32	-108
Consolidated Net Income / (Loss)	-0.32	-5.42	-32	-5.98	-7.66	-8.79	-4.73	-174	-45	-146
Net Income / (Loss) Continuing Operations	-0.32	-5.42	-32	-5.98	-7.66	-8.79	-4.73	-100	-21	-101
Total Pre-Tax Income	0.23	-4.83	-39	-5.08	-8.41	-8.19	-4.35	-100	-32	-131
Total Operating Income	7.99	4.07	-29	5.33	1.17	2.42	6.75	-92	-16	-127
Total Gross Profit	103	94	104	88	86	79	89	74	74	85
Total Revenue	154	139	151	129	135	121	137	119	126	129
Operating Revenue	154	139	151	129	135	121	137	119	126	129
Total Cost of Revenue	51	45	48	41	49	42	48	45	52	44
Operating Cost of Revenue	51	45	48	41	49	42	48	45	52	44
Total Operating Expenses	95	89	133	83	85	76	82	166	90	211
Selling, General & Admin Expense	87	81	95	78	78	70	75	81	77	79
Research & Development Expense	3.25	3.81	3.99	2.60	3.26	3.02	3.40	3.77	5.95	4.61
Depreciation Expense	1.77	2.07	2.06	1.76	2.10	2.32	2.29	2.13	1.54	2.26
Impairment Charge	2.46	2.03	32	0.00	-	0.00	0.00	79	-	125
Restructuring Charge	-0.05	0.00	0.00	0.00	-0.07	-0.03	0.62	0.32	4.62	0.58
Other Special Charges / (Income)	0.35	0.48	0.30	0.30	0.29	-0.10	0.24	0.29	0.28	0.28
Total Other Income / (Expense), net	-7.76	-8.91	-10	-10	-9.57	-11	-11	-8.11	-17	-3.72
Interest & Investment Income	-9.00	-9.53	-9.92	-10	-10	-10	-11	-9.69	-7.39	-3.60
Other Income / (Expense), net	1.24	0.63	-0.16	-0.06	0.71	-0.49	-0.51	1.59	-9.41	-0.12
Income Tax Expense	0.55	0.59	-7.34	0.91	-0.75	0.60	0.38	-0.15	-11	-30
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.16	-0.60	-8.12	-1.41	-1.56	-1.49	-1.05	-35	-13	-37
Basic Earnings per Share	($0.01)	($0.07)	($0.37)	($0.07)	($0.07)	($0.12)	($0.06)	($2.24)	($0.53)	($1.76)
Weighted Average Basic Shares Outstanding	64.55M	65.26M	64.06M	63.38M	62.65M	62.82M	62.55M	62.12M	61.39M	61.67M
Diluted Earnings per Share	($0.01)	($0.07)	($0.37)	($0.07)	($0.07)	($0.12)	($0.06)	($2.24)	($0.53)	($1.76)
Weighted Average Diluted Shares Outstanding	64.55M	65.26M	64.06M	63.38M	62.65M	62.82M	62.55M	62.12M	61.39M	61.67M
Weighted Average Basic & Diluted Shares Outstanding	81.94M	81.15M	80.97M	79.61M	79.17M	78.75M	78.58M	78.27M	78.05M	77.74M

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	4.62	5.13	-67
Net Cash From Operating Activities	39	15	-14
Net Cash From Continuing Operating Activities	39	18	-11
Net Income / (Loss) Continuing Operations	-44	-121	-145
Consolidated Net Income / (Loss)	-44	-196	-213
Net Income / (Loss) Discontinued Operations	0.00	-74	-69
Depreciation Expense	50	57	55
Non-Cash Adjustments To Reconcile Net Income	46	84	153
Changes in Operating Assets and Liabilities, net	-13	-3.13	-75
Net Cash From Discontinued Operating Activities	0.00	-2.17	-2.13
Net Cash From Investing Activities	23	16	-116
Net Cash From Continuing Investing Activities	23	27	-12
Purchase of Property, Plant & Equipment	-1.01	-7.36	-1.48
Acquisitions	-0.71	0.00	-10
Divestitures	25	35	0.00
Other Investing Activities, net	0.00	0.00	-0.08
Net Cash From Discontinued Investing Activities	0.00	-12	-105
Net Cash From Financing Activities	-55	-27	62
Net Cash From Continuing Financing Activities	-55	-27	62
Repayment of Debt	-62	-91	-45
Issuance of Debt	0.00	64	105
Issuance of Common Equity	2.44	0.78	5.82
Other Financing Activities, net	4.50	0.00	-3.35
Effect of Exchange Rate Changes	-2.56	0.63	0.52

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/28/2024	6/29/2024	3/30/2024	12/31/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Net Change in Cash & Equivalents	-1.49	11	6.82	-12	10	-2.56	-18	15	-2.55	-6.62
Net Cash From Operating Activities	19	10	15	-6.01	10	-8.32	11	2.49	5.24	-0.70
Net Cash From Continuing Operating Activities	19	10	15	-6.01	10	-8.32	11	4.66	6.52	0.16
Net Income / (Loss) Continuing Operations	-0.32	-5.42	-32	-5.98	-7.66	-8.79	-4.73	-100	-21	-101
Consolidated Net Income / (Loss)	-0.32	-5.42	-32	-5.98	-7.66	-8.79	-4.73	-174	-45	-146
Depreciation Expense	12	12	13	12	12	14	15	16	17	14
Non-Cash Adjustments To Reconcile Net Income	4.53	3.35	36	1.99	1.83	2.70	-2.34	82	15	129
Changes in Operating Assets and Liabilities, net	2.70	0.11	-1.96	-14	3.73	-16	3.27	5.92	-3.46	-42
Net Cash From Investing Activities	24	-0.06	-0.08	-1.00	-0.59	-2.04	34	-15	-3.40	-56
Net Cash From Continuing Investing Activities	24	-0.06	-0.08	-1.00	-0.59	-2.04	34	-3.56	-3.40	49
Purchase of Property, Plant & Equipment	-0.57	-0.06	-0.08	-0.29	-0.37	-2.04	-1.40	-3.56	5.16	-1.65
Divestitures	25	-	-	-	-0.22	-	-	-	-	-
Net Cash From Financing Activities	-43	0.36	-7.85	-4.24	-0.01	8.23	-62	27	-5.44	51
Net Cash From Continuing Financing Activities	-43	0.36	-7.85	-4.24	-0.01	8.23	-62	27	-5.44	51
Repayment of Debt	-50	-0.19	-8.45	-3.24	-3.83	-7.17	-60	-20	-6.52	-29
Issuance of Common Equity	1.10	0.55	0.61	0.18	0.16	0.40	0.14	0.08	1.08	0.48
Other Financing Activities, net	5.68	-	-	-1.18	3.66	-	-1.99	-1.67	-	-
Effect of Exchange Rate Changes	-2.06	0.47	-0.42	-0.54	0.37	-0.44	0.24	0.46	1.05	-0.24

This table presents Bioventus' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	728	811	1,373
Total Current Assets	276	268	273
Cash & Equivalents	42	37	30
Accounts Receivable	127	123	136
Inventories, net	92	91	85
Prepaid Expenses	14	17	19
Plant, Property, & Equipment, net	27	37	27
Total Noncurrent Assets	421	506	1,073
Long-Term Investments	1.89	3.14	2.62
Goodwill	7.46	7.46	7.46
Intangible Assets	405	482	640
Other Noncurrent Operating Assets	6.51	13	17
Total Liabilities & Shareholders' Equity	728	811	1,373
Total Liabilities	542	590	960
Total Current Liabilities	210	175	304
Short-Term Debt	47	28	33
Accounts Payable	24	23	37
Accrued Expenses	136	120	112
Other Current Liabilities	3.92	4.82	3.61
Total Noncurrent Liabilities	332	414	656
Long-Term Debt	308	367	385
Noncurrent Deferred & Payable Income Tax Liabilities	0.56	1.21	2.25
Other Noncurrent Operating Liabilities	23	46	40
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	186	221	412
Total Preferred & Common Equity	148	174	325
Total Common Equity	148	174	325
Common Stock	506	494	491
Retained Earnings	-355	-322	-165
Accumulated Other Comprehensive Income / (Loss)	-2.57	0.79	-0.11
Noncontrolling Interest	38	48	87

This table presents Bioventus' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/28/2024	6/29/2024	3/30/2024	9/30/2023	7/1/2023	4/1/2023	10/1/2022
Total Assets	769	792	794	811	837	887	1,398
Total Current Assets	299	309	266	249	261	309	271
Cash & Equivalents	43	32	25	27	29	47	34
Accounts Receivable	122	137	126	113	120	119	132
Inventories, net	90	88	97	98	96	88	77
Prepaid Expenses	17	24	18	12	15	17	28
Other Current Assets	27	28	-	-	-	38	-
Plant, Property, & Equipment, net	29	32	35	40	42	37	0.00
Total Noncurrent Assets	441	451	494	522	534	542	1,127
Long-Term Investments	1.93	2.09	3.21	6.86	6.54	2.62	13
Goodwill	7.46	7.46	7.46	7.46	7.46	7.46	15
Intangible Assets	415	425	471	493	505	516	1,056
Noncurrent Deferred & Refundable Income Taxes	7.40	6.88	-	-	-	-	0.00
Other Noncurrent Operating Assets	9.78	10	12	14	15	16	43
Total Liabilities & Shareholders' Equity	769	792	794	811	837	887	1,398
Total Liabilities	583	603	577	585	604	647	1,019
Total Current Liabilities	211	231	173	161	179	196	288
Short-Term Debt	58	57	36	20	11	41	31
Accounts Payable	17	24	19	18	41	33	19
Accrued Expenses	129	140	114	119	122	116	117
Other Current Liabilities	8.15	9.74	4.81	4.73	4.67	6.15	121
Total Noncurrent Liabilities	371	372	403	424	425	451	731
Long-Term Debt	345	345	355	375	375	404	393
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	0.00	1.29	0.00	0.00	0.35	159
Other Noncurrent Operating Liabilities	26	27	47	49	50	46	178
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	187	189	217	226	233	240	379
Total Preferred & Common Equity	149	151	171	178	183	189	343
Total Common Equity	149	151	171	178	183	189	343
Common Stock	503	501	497	493	491	493	478
Retained Earnings	-355	-350	-326	-315	-308	-304	-133
Accumulated Other Comprehensive Income / (Loss)	0.45	-0.02	0.33	0.40	0.66	0.41	-1.34
Noncontrolling Interest	38	38	46	49	50	52	36

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	11.89%	0.04%	18.85%
EBITDA Growth	270.01%	81.03%	-367.41%
EBIT Growth	87.15%	54.56%	-1,769.85%
NOPAT Growth	85.34%	51.13%	-904.00%
Net Income Growth	77.59%	8.33%	-2,326.07%
EPS Growth	79.12%	3.86%	-1,626.67%
Operating Cash Flow Growth	152.84%	213.35%	-158.88%
Free Cash Flow Firm Growth	-27.74%	353.99%	92.87%
Invested Capital Growth	-14.46%	-21.83%	-9.38%
Revenue Q/Q Growth	3.28%	1.91%	-0.89%
EBITDA Q/Q Growth	22.85%	49.32%	-17.38%
EBIT Q/Q Growth	41.58%	25.08%	-15.13%
NOPAT Q/Q Growth	36.29%	17.05%	-8.07%
Net Income Q/Q Growth	14.34%	15.98%	-25.22%
EPS Q/Q Growth	10.34%	15.59%	-25.73%
Operating Cash Flow Q/Q Growth	29.98%	50.23%	-139.00%
Free Cash Flow Firm Q/Q Growth	153.18%	3.87%	92.63%
Invested Capital Q/Q Growth	-9.56%	-1.96%	-2.57%
Profitability Metrics	-	-	-
Gross Margin	67.72%	64.06%	64.65%
EBITDA Margin	6.84%	-4.50%	-23.75%
Operating Margin	-2.09%	-15.95%	-32.66%
EBIT Margin	-1.80%	-15.70%	-34.56%
Profit (Net Income) Margin	-7.65%	-38.18%	-41.67%
Tax Burden Percent	89.23%	161.53%	112.89%
Interest Burden Percent	475.38%	150.57%	106.79%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1.57%	-8.72%	-15.11%
ROIC Less NNEP Spread (ROIC-NNEP)	-12.28%	-49.47%	-47.02%
Return on Net Nonoperating Assets (RNNOA)	-19.98%	-53.06%	-30.01%
Return on Equity (ROE)	-21.55%	-61.78%	-45.11%
Cash Return on Invested Capital (CROIC)	14.02%	15.79%	-5.27%
Operating Return on Assets (OROA)	-1.34%	-7.37%	-13.62%
Return on Assets (ROA)	-5.70%	-17.92%	-16.42%
Return on Common Equity (ROCE)	-17.04%	-48.66%	-37.40%
Return on Equity Simple (ROE_SIMPLE)	-29.63%	-112.69%	-65.61%
Net Operating Profit after Tax (NOPAT)	-8.39	-57	-117
NOPAT Margin	-1.46%	-11.17%	-22.86%
Net Nonoperating Expense Percent (NNEP)	10.71%	40.76%	31.91%
Return On Investment Capital (ROIC_SIMPLE)	-1.55%	-9.29%	-14.10%
Cost of Revenue to Revenue	32.28%	35.94%	35.35%
SG&A Expenses to Revenue	59.46%	59.31%	64.86%
R&D to Revenue	2.38%	2.62%	4.66%
Operating Expenses to Revenue	69.81%	80.01%	97.30%
Earnings before Interest and Taxes (EBIT)	-10	-80	-177
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	39	-23	-122
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.76	2.39	0.62
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.49	0.81	0.40
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.44	1.42	0.92
Enterprise Value to Revenue (EV/Rev)	2.10	1.60	1.32
Enterprise Value to EBITDA (EV/EBITDA)	30.63	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	30.97	53.26	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	16.04	7.89	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.91	1.79	1.01
Long-Term Debt to Equity	1.66	1.66	0.93
Financial Leverage	1.63	1.07	0.64
Leverage Ratio	3.78	3.45	2.75
Compound Leverage Factor	17.99	5.19	2.93
Debt to Total Capital	65.68%	64.10%	50.35%
Short-Term Debt to Total Capital	8.67%	4.52%	3.98%
Long-Term Debt to Total Capital	57.01%	59.58%	46.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	6.96%	7.72%	10.48%
Common Equity to Total Capital	27.36%	28.18%	39.17%
Debt to EBITDA	9.06	-17.12	-3.44
Net Debt to EBITDA	7.95	-15.38	-3.17
Long-Term Debt to EBITDA	7.86	-15.91	-3.17
Debt to NOPAT	-42.36	-6.90	-3.57
Net Debt to NOPAT	-37.18	-6.20	-3.29
Long-Term Debt to NOPAT	-36.77	-6.42	-3.29
Altman Z-Score	1.11	0.31	-0.12
Noncontrolling Interest Sharing Ratio	20.95%	21.24%	17.11%
Liquidity Ratios	-	-	-
Current Ratio	1.31	1.53	0.90
Quick Ratio	0.80	0.91	0.55
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	75	104	-41
Operating Cash Flow to CapEx	3,856.36%	208.42%	-915.90%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.75	0.47	0.39
Accounts Receivable Turnover	4.58	3.96	3.92
Inventory Turnover	2.01	2.09	2.47
Fixed Asset Turnover	18.02	16.00	20.31
Accounts Payable Turnover	7.92	6.17	6.75
Days Sales Outstanding (DSO)	79.64	92.29	93.10
Days Inventory Outstanding (DIO)	181.27	174.52	147.64
Days Payable Outstanding (DPO)	46.08	59.20	54.05
Cash Conversion Cycle (CCC)	214.83	207.61	186.70
Capital & Investment Metrics	-	-	-
Invested Capital	493	576	737
Invested Capital Turnover	1.07	0.78	0.66
Increase / (Decrease) in Invested Capital	-83	-161	-76
Enterprise Value (EV)	1,202	817	675
Market Capitalization	852	415	203
Book Value per Share	$1.82	$2.20	$4.18
Tangible Book Value per Share	($3.26)	($4.02)	($4.14)
Total Capital	541	616	830
Total Debt	355	395	418
Total Long-Term Debt	308	367	385
Net Debt	312	355	385
Capital Expenditures (CapEx)	1.01	7.36	1.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)	71	83	-29
Debt-free Net Working Capital (DFNWC)	112	120	1.61
Net Working Capital (NWC)	65	93	-31
Net Nonoperating Expense (NNE)	35	138	96
Net Nonoperating Obligations (NNO)	307	355	324
Total Depreciation and Amortization (D&A)	50	57	55
Debt-free, Cash-free Net Working Capital to Revenue	12.31%	16.28%	-5.58%
Debt-free Net Working Capital to Revenue	19.56%	23.49%	0.32%
Net Working Capital to Revenue	11.38%	18.05%	-6.14%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.52)	($2.49)	($2.59)
Adjusted Weighted Average Basic Shares Outstanding	64.55M	62.65M	61.39M
Adjusted Diluted Earnings per Share	($0.52)	($2.49)	($2.59)
Adjusted Weighted Average Diluted Shares Outstanding	64.55M	62.65M	61.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.94M	79.17M	78.05M
Normalized Net Operating Profit after Tax (NOPAT)	18	-1.09	-24
Normalized NOPAT Margin	3.14%	-0.21%	-4.74%
Pre Tax Income Margin	-8.57%	-23.64%	-36.91%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/28/2024	6/29/2024	3/30/2024	12/31/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.45%	15.04%	10.32%	8.73%	7.62%	-6.12%	-2.32%	1.51%	-3.51%	18.16%
EBITDA Growth	50.88%	7.77%	-178.88%	123.04%	276.83%	113.89%	145.95%	-759.63%	-181.91%	-1,787.42%
EBIT Growth	392.48%	144.28%	-573.42%	105.82%	107.48%	101.52%	259.43%	-329.03%	-1,299.50%	-6,937.36%
NOPAT Growth	-1,442.62%	68.49%	-535.08%	105.79%	107.45%	101.91%	304.05%	-329.17%	-396.41%	-12,014.52%
Net Income Growth	95.85%	38.33%	-578.76%	96.57%	82.94%	93.97%	40.97%	-1,078.22%	-2,270.47%	-6,321.24%
EPS Growth	85.71%	41.67%	-516.67%	96.88%	86.79%	93.18%	45.45%	-1,078.95%	0.00%	-5,766.67%
Operating Cash Flow Growth	86.25%	224.06%	40.45%	-341.16%	97.83%	-1,086.16%	267.30%	111.85%	-60.02%	-106.62%
Free Cash Flow Firm Growth	-55.26%	-73.25%	-97.07%	-53.43%	147.52%	131.93%	137.65%	122.23%	111.09%	-71.20%
Invested Capital Growth	-14.46%	-7.28%	-4.51%	-8.79%	-21.83%	-22.32%	-24.70%	-23.23%	-9.38%	143.06%
Revenue Q/Q Growth	10.56%	-8.10%	16.81%	-4.41%	12.11%	-11.87%	15.13%	-5.38%	-2.20%	-8.32%
EBITDA Q/Q Growth	27.45%	203.27%	-196.41%	18.90%	-8.96%	-24.41%	128.16%	-812.53%	92.85%	-1,438.07%
EBIT Q/Q Growth	96.36%	115.92%	-660.92%	180.90%	-2.60%	-69.15%	106.89%	-261.14%	80.27%	-3,145.25%
NOPAT Q/Q Growth	-483.94%	113.87%	-651.30%	357.25%	-51.82%	-64.18%	107.33%	-488.72%	87.67%	-3,734.31%
Net Income Q/Q Growth	94.13%	83.12%	-436.81%	21.87%	12.91%	-85.82%	97.29%	-288.76%	69.20%	-1,718.04%
EPS Q/Q Growth	85.71%	81.08%	-428.57%	0.00%	41.67%	-100.00%	97.32%	-322.64%	69.89%	-1,500.00%
Operating Cash Flow Q/Q Growth	87.30%	-31.96%	352.49%	-157.89%	224.76%	-177.03%	333.53%	-52.52%	848.07%	-123.85%
Free Cash Flow Firm Q/Q Growth	58.63%	694.80%	-90.39%	-63.09%	-5.15%	-13.09%	53.07%	96.16%	112.23%	-2.49%
Invested Capital Q/Q Growth	-9.56%	-2.22%	-4.01%	0.77%	-1.96%	0.70%	-8.32%	-13.64%	-2.57%	-2.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.82%	67.32%	68.54%	68.27%	63.73%	65.28%	65.02%	62.09%	58.96%	65.70%
EBITDA Margin	14.08%	12.22%	-10.87%	13.17%	10.59%	13.04%	15.20%	-62.15%	-6.44%	-88.11%
Operating Margin	5.20%	2.93%	-19.42%	4.11%	0.86%	2.00%	4.92%	-77.32%	-12.43%	-98.58%
EBIT Margin	6.01%	3.38%	-19.53%	4.07%	1.38%	1.59%	4.55%	-75.99%	-19.91%	-98.67%
Profit (Net Income) Margin	-0.21%	-3.90%	-21.24%	-4.62%	-5.65%	-7.28%	-3.45%	-146.52%	-35.66%	-113.24%
Tax Burden Percent	-137.07%	112.19%	81.40%	117.87%	91.08%	107.33%	108.76%	174.16%	138.33%	111.60%
Interest Burden Percent	2.51%	-102.81%	133.61%	-96.41%	-448.56%	-425.73%	-69.75%	110.72%	129.50%	102.84%
Effective Tax Rate	237.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.65%	2.01%	-12.80%	2.48%	0.47%	1.05%	2.59%	-37.97%	-5.75%	-66.82%
ROIC Less NNEP Spread (ROIC-NNEP)	-4.43%	-0.29%	-16.02%	-0.08%	-2.02%	-1.79%	-0.54%	-69.28%	-16.99%	-91.70%
Return on Net Nonoperating Assets (RNNOA)	-7.21%	-0.50%	-27.23%	-0.14%	-2.17%	-2.18%	-0.43%	-63.87%	-10.84%	-68.82%
Return on Equity (ROE)	-14.86%	1.51%	-40.03%	2.34%	-1.70%	-1.14%	2.16%	-101.84%	-16.59%	-135.64%
Cash Return on Invested Capital (CROIC)	14.02%	5.23%	2.10%	11.00%	15.79%	14.85%	4.70%	3.56%	-5.27%	-103.70%
Operating Return on Assets (OROA)	4.48%	2.38%	-12.87%	2.53%	0.65%	0.73%	2.27%	-37.47%	-7.85%	-49.67%
Return on Assets (ROA)	-0.15%	-2.74%	-14.00%	-2.87%	-2.65%	-3.31%	-1.72%	-72.24%	-14.06%	-57.01%
Return on Common Equity (ROCE)	-11.75%	1.19%	-31.66%	1.84%	-1.34%	-0.98%	1.81%	-85.27%	-13.75%	-110.34%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-34.40%	-36.14%	-15.86%	0.00%	-131.16%	-201.83%	-197.88%	0.00%	-49.63%
Net Operating Profit after Tax (NOPAT)	-11	2.85	-21	3.73	0.82	1.69	4.73	-64	-11	-89
NOPAT Margin	-7.13%	2.05%	-13.59%	2.88%	0.60%	1.40%	3.45%	-54.12%	-8.70%	-69.01%
Net Nonoperating Expense Percent (NNEP)	-3.21%	2.30%	3.22%	2.56%	2.49%	2.84%	3.13%	31.31%	11.24%	24.87%
Return On Investment Capital (ROIC_SIMPLE)	-2.02%	-	-	-	0.13%	-	-	-	-1.32%	-
Cost of Revenue to Revenue	33.18%	32.68%	31.46%	31.73%	36.27%	34.72%	34.98%	37.91%	41.04%	34.30%
SG&A Expenses to Revenue	56.37%	58.35%	62.68%	60.57%	57.86%	57.80%	54.60%	67.91%	61.54%	61.37%
R&D to Revenue	2.11%	2.74%	2.64%	2.01%	2.41%	2.50%	2.48%	3.17%	4.73%	3.59%
Operating Expenses to Revenue	61.62%	64.39%	87.96%	64.15%	62.87%	63.27%	60.10%	139.41%	71.38%	164.29%
Earnings before Interest and Taxes (EBIT)	9.23	4.70	-30	5.26	1.87	1.92	6.24	-90	-25	-127
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	22	17	-16	17	14	16	21	-74	-8.11	-113
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.76	6.34	3.03	2.40	2.39	1.46	1.23	0.44	0.62	1.58
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.49	1.70	0.85	0.79	0.81	0.52	0.44	0.16	0.40	1.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.44	2.46	1.55	1.41	1.42	1.14	1.07	0.84	0.92	1.26
Enterprise Value to Revenue (EV/Rev)	2.10	2.41	1.61	1.57	1.60	1.33	1.23	1.03	1.32	1.85
Enterprise Value to EBITDA (EV/EBITDA)	30.63	41.92	28.14	12.07	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	53.64	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	74.87	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	30.97	44.84	77.02	119.82	53.26	65.51	35.13	53.27	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	16.04	45.25	72.15	12.27	7.89	6.71	19.61	20.38	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.91	2.16	2.13	1.80	1.79	1.74	1.65	1.85	1.01	1.12
Long-Term Debt to Equity	1.66	1.85	1.82	1.63	1.66	1.66	1.61	1.68	0.93	1.04
Financial Leverage	1.63	1.74	1.70	1.66	1.07	1.22	0.80	0.92	0.64	0.75
Leverage Ratio	3.78	3.82	3.86	3.67	3.45	3.65	2.71	2.73	2.75	3.37
Compound Leverage Factor	0.10	-3.93	5.15	-3.54	-15.46	-15.53	-1.89	3.03	3.56	3.46
Debt to Total Capital	65.68%	68.31%	68.01%	64.28%	64.10%	63.54%	62.32%	64.96%	50.35%	52.82%
Short-Term Debt to Total Capital	8.67%	9.80%	9.70%	5.88%	4.52%	3.15%	1.83%	6.02%	3.98%	3.90%
Long-Term Debt to Total Capital	57.01%	58.51%	58.32%	58.39%	59.58%	60.38%	60.49%	58.94%	46.37%	48.92%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	6.96%	6.46%	6.45%	7.58%	7.72%	7.88%	8.10%	7.56%	10.48%	4.45%
Common Equity to Total Capital	27.36%	25.22%	25.54%	28.14%	28.18%	28.58%	29.58%	27.48%	39.17%	42.74%
Debt to EBITDA	9.06	12.62	13.09	5.76	-17.12	-8.67	-2.21	-2.38	-3.44	-4.10
Net Debt to EBITDA	7.95	11.21	11.98	5.34	-15.38	-7.93	-2.00	-2.12	-3.17	-3.64
Long-Term Debt to EBITDA	7.86	10.81	11.23	5.23	-15.91	-8.24	-2.14	-2.16	-3.17	-3.79
Debt to NOPAT	-42.36	-30.61	-28.07	35.69	-6.90	-5.72	-2.42	-2.68	-3.57	-3.92
Net Debt to NOPAT	-37.18	-27.19	-25.69	33.10	-6.20	-5.23	-2.19	-2.38	-3.29	-3.48
Long-Term Debt to NOPAT	-36.77	-26.21	-24.07	32.42	-6.42	-5.44	-2.35	-2.43	-3.29	-3.63
Altman Z-Score	1.20	1.20	0.51	0.67	0.64	0.48	0.46	-0.01	0.24	0.24
Noncontrolling Interest Sharing Ratio	20.95%	21.06%	20.90%	21.41%	21.24%	13.98%	16.24%	16.27%	17.11%	18.66%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.31	1.41	1.33	1.53	1.53	1.55	1.46	1.57	0.90	0.94
Quick Ratio	0.80	0.78	0.73	0.87	0.91	0.87	0.83	0.84	0.55	0.58
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	72	46	5.74	60	162	170	196	128	65	-534
Operating Cash Flow to CapEx	3,366.20%	16,118.75%	19,690.91%	-2,063.57%	2,811.38%	-408.40%	772.73%	69.94%	0.00%	-42.51%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.75	0.70	0.66	0.62	0.47	0.46	0.50	0.49	0.39	0.50
Accounts Receivable Turnover	4.58	4.73	4.18	4.28	3.96	4.10	3.89	4.32	3.92	4.35
Inventory Turnover	2.01	1.95	1.95	1.95	2.09	2.14	2.28	2.42	2.47	3.03
Fixed Asset Turnover	18.02	16.06	14.55	14.71	16.00	0.00	15.25	16.74	20.31	0.00
Accounts Payable Turnover	7.92	10.62	5.46	6.94	6.17	10.17	5.63	6.67	6.75	11.48
Days Sales Outstanding (DSO)	79.64	77.21	87.34	85.21	92.29	88.97	93.87	84.46	93.10	83.93
Days Inventory Outstanding (DIO)	181.27	186.89	186.73	187.43	174.52	170.61	159.79	150.92	147.64	120.42
Days Payable Outstanding (DPO)	46.08	34.36	66.82	52.62	59.20	35.89	64.84	54.70	54.05	31.79
Cash Conversion Cycle (CCC)	214.83	229.74	207.25	220.03	207.61	223.69	188.82	180.68	186.70	172.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	493	545	557	580	576	587	583	636	737	756
Invested Capital Turnover	1.07	0.98	0.94	0.86	0.78	0.75	0.75	0.70	0.66	0.97
Increase / (Decrease) in Invested Capital	-83	-43	-26	-56	-161	-169	-191	-193	-76	445
Enterprise Value (EV)	1,202	1,338	864	821	817	669	626	531	675	955
Market Capitalization	852	943	458	412	415	259	226	84	203	542
Book Value per Share	$1.82	$1.84	$1.90	$2.16	$2.20	$2.26	$2.34	$2.42	$4.18	$4.43
Tangible Book Value per Share	($3.26)	($3.38)	($3.53)	($3.88)	($4.02)	($4.11)	($4.21)	($4.29)	($4.14)	($9.39)
Total Capital	541	590	591	609	616	621	619	686	830	804
Total Debt	355	403	402	391	395	395	386	446	418	424
Total Long-Term Debt	308	345	345	355	367	375	375	404	385	393
Net Debt	312	358	368	363	355	361	350	396	385	377
Capital Expenditures (CapEx)	0.57	0.06	0.08	0.29	0.37	2.04	1.40	3.56	-5.16	1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	71	102	103	103	83	81	63	107	-29	-20
Debt-free Net Working Capital (DFNWC)	112	145	135	128	120	108	93	154	1.61	14
Net Working Capital (NWC)	65	87	77	93	93	89	82	113	-31	-17
Net Nonoperating Expense (NNE)	-11	8.27	12	9.71	8.47	10	9.46	110	34	57
Net Nonoperating Obligations (NNO)	307	358	368	363	355	361	350	396	324	377
Total Depreciation and Amortization (D&A)	12	12	13	12	12	14	15	16	17	14
Debt-free, Cash-free Net Working Capital to Revenue	12.31%	18.36%	19.14%	19.75%	16.28%	16.18%	12.43%	20.79%	-5.58%	-3.94%
Debt-free Net Working Capital to Revenue	19.56%	26.12%	25.09%	24.56%	23.49%	21.52%	18.18%	29.95%	0.32%	2.71%
Net Working Capital to Revenue	11.38%	15.71%	14.42%	17.71%	18.05%	17.62%	15.97%	21.91%	-6.14%	-3.35%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.01)	($0.07)	($0.37)	($0.07)	($0.07)	($0.12)	($0.06)	($2.24)	($0.53)	($1.76)
Adjusted Weighted Average Basic Shares Outstanding	64.55M	65.26M	64.06M	63.38M	62.65M	62.82M	62.55M	62.12M	61.39M	61.67M
Adjusted Diluted Earnings per Share	($0.01)	($0.07)	($0.37)	($0.07)	($0.07)	($0.12)	($0.06)	($2.24)	($0.53)	($1.76)
Adjusted Weighted Average Diluted Shares Outstanding	64.55M	65.26M	64.06M	63.38M	62.65M	62.82M	62.55M	62.12M	61.39M	61.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	81.94M	81.15M	80.97M	79.61M	79.17M	78.75M	78.58M	78.27M	78.05M	77.74M
Normalized Net Operating Profit after Tax (NOPAT)	7.52	4.61	1.96	3.94	0.97	1.61	5.33	-8.99	-7.51	-0.90
Normalized NOPAT Margin	4.89%	3.32%	1.30%	3.04%	0.72%	1.33%	3.89%	-7.55%	-5.97%	-0.70%
Pre Tax Income Margin	0.15%	-3.48%	-26.09%	-3.92%	-6.21%	-6.78%	-3.17%	-84.13%	-25.78%	-101.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Bioventus' Financials

When does Bioventus's fiscal year end?

According to the most recent income statement we have on file, Bioventus' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bioventus' net income changed over the last 2 years?

Bioventus' net income appears to be on a downward trend, with a most recent value of -$43.83 million in 2024, falling from -$213.39 million in 2022. The previous period was -$195.63 million in 2023. Find out what analysts predict for Bioventus in the coming months.

What is Bioventus's operating income?

Bioventus's total operating income in 2024 was -$11.98 million, based on the following breakdown:

Total Gross Profit: $388.23 million
Total Operating Expenses: $400.21 million

How has Bioventus revenue changed over the last 2 years?

Over the last 2 years, Bioventus' total revenue changed from $512.12 million in 2022 to $573.28 million in 2024, a change of 11.9%.

How much debt does Bioventus have?

Bioventus' total liabilities were at $542.35 million at the end of 2024, a 8.0% decrease from 2023, and a 43.5% decrease since 2022.

How much cash does Bioventus have?

In the past 2 years, Bioventus' cash and equivalents has ranged from $30.19 million in 2022 to $41.58 million in 2024, and is currently $41.58 million as of their latest financial filing in 2024.

How has Bioventus' book value per share changed over the last 2 years?

Over the last 2 years, Bioventus' book value per share changed from 4.18 in 2022 to 1.82 in 2024, a change of -56.4%.

Related Companies

This page (NYSE:BVS) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Financials

Frequently Asked Questions About Bioventus' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Financials

Annual Income Statements for Bioventus

Quarterly Income Statements for Bioventus

Annual Cash Flow Statements for Bioventus

Quarterly Cash Flow Statements for Bioventus

Annual Balance Sheets for Bioventus

Quarterly Balance Sheets for Bioventus

Annual Metrics And Ratios for Bioventus

Quarterly Metrics And Ratios for Bioventus

Frequently Asked Questions About Bioventus' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools